WARNING:  THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/30/2022

PRODUCT INFORMATION

Fasnall (benzenesulfonate)
Item No. 19957

CAS Registry No.: 2187367-11-7
Formal Name: 5,6-dimethyl-N-[1-(phenylmethyl)-3-pyrrolidinyl]-thieno[2,3-d]pyrimidin-4-amine, monobenzenesulfonate
MF: C_{19}H_{22}N_{4}S • C_{6}H_{6}O_{3}S
FW: 496.6
Purity: ≥98%
UV/Vis.: λ_{max}: 212, 279 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Fasnall (benzenesulfonate) is supplied as a crystalline solid. A stock solution may be made by dissolving the fasnall (benzenesulfonate) in the solvent of choice, which should be purged with an inert gas. Fasnall (benzenesulfonate) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of fasnall (benzenesulfonate) in these solvents is approximately 30 mg/ml.

Description

Fasnall is an inhibitor of fatty acid synthase (FASN) with an IC_{50} value of 3.71 μM for the human recombinant enzyme.\textsuperscript{1} It inhibits tritiated acetate incorporation into lipids (IC_{50} = 5.84 μM), increases ceramide accumulation, and induces the formation of lipid droplets in BT474 HER2\textsuperscript{+} breast cancer cells. Fasnall has antiproliferative activity against non-tumorigenic MCF-10A and tumorigenic MCF-7, MDA-MB-468, BT474, and SK-BR-3 breast cancer cells that directly correlates to the level of FASN expression in vitro. It reduces tumor volume and increases survival in the murine MMTV-Neu model of HER2\textsuperscript{+} breast cancer. Fasnall also potentiates carboplatin (Item No. 13112) response in vivo, increasing the objective response rate of stable disease from 25% for carboplatin alone to 88% for carboplatin with fasnall.

Reference